AQST Aquestive Therapeutics, Inc. Common Stock
XNAS
3.97
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
AQST
$3.97
—
Key stats
$3.97
Pre-market
$3.98
+0.25%
- 52-Week Range
- $2.93 – $7.08
- YTD
- -38.45%
- IV Rank (30D)
- 58.25
- Straddle Price
- $0.57
- P/C Vol Ratio
- 0.94
- Market Cap
- $0.5B
- Open
- $4.00
- Day Range
- $3.94 – $4.04
- Volume
- 1,273,417
- Prev Close
- $4.00
Fair Value
+20.7% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.29 |
| Cost of Equity (CAPM) | 12.06% (VRP-adj) |
| WACC | 11.56% |
| Volatility Risk Premium | +106.2pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +7.9% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.08 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | 138.2% |
| Book / Price | -11.9% |
| Gross Margin (TTM) | 67.0% |
| FCF Margin (TTM) | -85.0% |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $4.69 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $4.38 |
| Bollinger Width / SMA20 | 705.3% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: ABEO, ACHV, CLDX, CORT, DCTH, MIST, PHAT, ZVRA
Blended Fair Value
$4.79
Deviation
+20.7%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 170.3× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 10.8× · 3 peers |
| Peer P/B | n/a | 0% | median 3.2× · 5 peers |
| Peer P/S | $4.79 | 100% | median 9.9× · 7 peers |
| Market Anchor (SMA50) | $4.69 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $3.65 | 0% | 5 strikes · skew +0.22 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.5B
- Employees
- 147
- List Date
- 2018-07-25
- CIK
- 0001398733
- Next Earnings
- 2026-11-04 (After-Close)
- EPS Forecast
- ($0.10) (2 est.)
- Headquarters
- Warren, NJ
- Homepage
- https://www.aquestive.com
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -4.51% | -36.15% | -1.10% | 18.91% | -17.71% | -54.26% | -15.80% |
| Feb | -13.42% | -1.76% | -11.07% | 37.45% | -3.11% | -2.44% | 0.94% |
| Mar | -1.70% | -9.38% | 48.03% | 0.47% | 9.43% | -1.43% | 7.57% |
| Apr | -20.82% | -45.53% | 26.42% | -18.64% | 2.27% | -0.73% | -9.51% |
| May | -6.78% | -29.50% | 66.19% | -14.41% | -9.67% | -4.29% | 0.26% |
| Jun | 5.59% | -34.52% | -28.57% | -11.56% | 17.79% | 4.00% | -7.88% |
| Jul | -16.88% | 30.48% | 36.02% | 56.73% | 12.94% | -12.75% | 17.76% |
| Aug | 38.37% | 68.59% | -26.79% | 26.18% | -1.31% | 34.83% | 23.31% |
| Sep | -5.83% | -9.30% | -8.38% | 18.85% | 45.95% | -11.64% | 4.94% |
| Oct | 20.37% | -26.27% | 12.14% | 15.34% | 15.99% | -10.59%* | 4.50% |
| Nov | 12.60% | 8.47% | 46.10% | -7.79% | -4.62% | -- | 10.95% |
| Dec | -31.63% | -3.50% | -15.48% | -25.99% | 4.19% | -- | -14.48% |
| Total | -36.43% | -77.99% | 146.85% | 87.10% | 78.02% | -59.61% | 22.99% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $4.38
SMA 50: $4.69
SMA 200: $4.20
Current: $3.97
EMA 12: $4.18
EMA 26: $4.38
MACD: -0.1986 | Signal: -0.0461
BEARISH
ADX (14): 21.12
WEAK TREND
+DI: 18.38
−DI: 31.06
Momentum Oscillators
RSI (14): 36.36
NEUTRAL
Stoch %K: 28.93
Stoch %D: 31.19
Williams %R: -75.85
Volume & Volatility
BB Upper: $5.06
BB Lower: $3.70
NEUTRAL
OBV: 837,719
Vol SMA 20: 2,171,394
Vol ROC: 32.80%
ATR: $0.23
True Range: $0.10
HV 20: 62.0%
HV 30: 57.2%
HV 60: 55.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary BULLISH (confidence level: 6/10) Key drivers: Strong technical momentum, bullish MACD signal, and low volatility. Primary risks: Negative news sentiment and potential catalysts for increased volatility.
Investment thesis: AQST is likely to continue its upward trend due to the strong technical momentum and low volatility. However, investors should be cautious of potential negative news sentiment and increased volatility.
Recent news sentiment impact: The recent news headlines have been predominantly negative, which may affect the stock's price in the short term.
Technical Analysis Trend Direction:
- Short-term (1-4 weeks): Bullish
- Medium-term (1-3 months): Neutral
- Long-term (3-12 months): Bullish
Support/Resistance Levels: The key price levels to monitor are $5.66 (upper Bollinger Band), $4.78 (SMA 20), and $3.91 (lower Bollinger Band).
Momentum Signals:
- RSI interpretation: Overbought (>70), indicating potential for a pullback.
- MACD signal: Bullish, confirming the upward trend.
- Bollinger Bands position: Neutral, indicating mean reversion.
Volume Analysis: The volume trends and institutional interest signals are moderate, with an increasing volume rate of change (4.95%).
News & Sentiment Analysis Recent Headlines Summary: The recent news headlines have been predominantly negative, focusing on securities class actions and investor harm.
Sentiment Assessment: The aggregate news sentiment is NEGATIVE, which may affect the stock's price in the short term.
Catalyst Identification: There are no immediate catalysts for increased volatility. However, investors should monitor the earnings information and options activity for potential changes.
Market Narrative: The negative news sentiment strongly contradicts the technical signals, indicating a potential divergence between the market and the company's fundamentals.
Risk & Volatility Assessment Beta Interpretation: Moderate risk relative to the market (beta 0.90).
Volatility Regime: Current volatility is moderate (54.8% HV20), with an IV premium vs HV30 of 92.8%, indicating implied richer than realized volatility.
Options Market Signals:
- IV rank: Low, showing historically low volatility.
- Put/call ratio: Bullish, with more calls traded than puts.
Downside Protection: The key support levels to monitor are $4.78 (SMA 20) and $3.91 (lower Bollinger Band).
Market Context & Positioning Sector Performance: AQST is relatively strong within its sector, with a beta of 0.90 compared to the SPY.
Institutional Activity: The institutional interest signals are moderate, with an increasing volume rate of change (4.95%).
Correlation Analysis: The stock's movement is correlated with the market (R-squared interpretation), indicating a relatively low-risk profile.
Relative Valuation: AQST is positioned within its trading range, with a relative valuation that indicates potential for further upward momentum.
Key Levels & Action Items Critical Price Levels:
- $5.66 (upper Bollinger Band)
- $4.78 (SMA 20)
- $3.91 (lower Bollinger Band)
Breakout/Breakdown Levels: The key technical levels to monitor are the SMA 20, SMA 50, and upper/lower Bollinger Bands.
Time-Sensitive Catalysts: Monitor earnings information for potential catalysts for increased volatility or changes in sentiment.
Risk Management:
- Stop-loss levels: $4.78 (SMA 20) and $3.91 (lower Bollinger Band)
- Position sizing considerations: Adjust position size based on market conditions and risk tolerance.
Generated
News
All AQST news →
Earnings History
21 of 22 under expected move
Avg Expected Move
63.48%
Avg Actual Move
7.62%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-03-09 | After-Close | 29.31% | 6.26% | 0.21x | Within |
| 2021-05-04 | After-Close | 76.71% | 5.48% | 0.07x | Within |
| 2021-08-03 | After-Close | 30.77% | 13.23% | 0.43x | Within |
| 2021-11-02 | After-Close | 16.79% | 10.07% | 0.60x | Within |
| 2022-03-08 | After-Close | 21.28% | 0.71% | 0.03x | Within |
| 2022-05-04 | After-Close | 84.51% | 10.56% | 0.12x | Within |
| 2022-11-01 | After-Close | 473.41% | 1.81% | 0.00x | Within |
| 2023-03-07 | After-Close | 192.94% | 0.00% | 0.00x | Within |
| 2023-05-02 | After-Close | 107.91% | 20.86% | 0.19x | Within |
| 2023-08-07 | After-Close | 30.73% | 5.37% | 0.17x | Within |
| 2024-03-05 | After-Close | 47.73% | 20.05% | 0.42x | Within |
| 2024-05-07 | After-Close | 17.75% | 8.73% | 0.49x | Within |
| 2024-08-06 | Pre-Market | 59.27% | 3.34% | 0.06x | Within |
| 2024-11-04 | After-Close | 20.87% | 7.67% | 0.37x | Within |
| 2025-01-13 | After-Close | 24.92% | 1.93% | 0.08x | Within |
| 2025-03-05 | After-Close | 25.99% | 7.53% | 0.29x | Within |
| 2025-05-12 | After-Close | 28.95% | 19.65% | 0.68x | Within |
| 2025-08-11 | Pre-Market | 44.87% | 1.03% | 0.02x | Within |
| 2025-11-05 | After-Close | 22.08% | 2.17% | 0.10x | Within |
| 2026-03-04 | After-Close | 16.59% | 2.52% | 0.15x | Within |
| 2026-05-13 | After-Close | 8.47% | 14.53% | 1.72x | Exceeded |
| 2026-08-11 | After-Close | 14.74% | 4.08% | 0.28x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
AQST Options Activity & IV Rank
AQST IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 96.9%
7-DTE IV: —
Expected Move: $0.57
7-DTE Move: $0.57
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 82
Put Volume: 77
P/C Volume: 0.939
NEUTRAL
Call OI: 21,776
Put OI: 22,623
P/C OI: 1.039
Total OI: 44,399
ATM Options Pricing
ATM Call: $0.30
ATM Put: $0.28
Call %: 7.6%
Put %: 6.9%
Chain Summary
Chain Volume: 4,676
Chain OI: 78,177
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 1st percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
1%
vs own history
GEX tilt
-0.85
OI-weighted, today
Vanna tilt
-0.78
δ-sensitivity to IV
Charm tilt
+0.80
δ-decay vs time
Vanna tilt -0.78: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.80: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 5 ATM contracts, 17k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 69.0% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)58.2MediumOct 26
Straddle Price (30 DTE)$0.57Oct 26
Beta Analysis
Risk Metrics
Beta: 0.8108
Alpha: -34.72%
Correlation: 0.1340
R-Squared: 1.8%
Stock Volatility: 77.1%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own AQST
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $1.9M | #2987 of 6285 | -20.0% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $1.7M | #2048 of 3138 | new | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $69K | #3188 of 4729 | -11.7% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
AQST Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 120,121,628 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
8 filers$14.00M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $7.90M | 56.44% | 2026-06-30 |
| 2 | DIADEMA PARTNERS LP | $1.79M | 12.75% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $1.61M | 11.48% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $1.25M | 8.93% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $957.63K | 6.84% | 2026-06-30 |
| 6 | IMC-Chicago, LLC Custodian | $290.37K | 2.07% | 2026-06-30 |
| 7 | Jane Street Group, LLC Custodian | $205.50K | 1.47% | 2026-06-30 |
| 8 | Persistent Asset Partners Ltd | $2.59K | 0.02% | 2026-06-30 |
6 filers$3.79M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $2.57M | 67.85% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $544.96K | 14.37% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $217.98K | 5.75% | 2026-06-30 |
| 4 | IMC-Chicago, LLC Custodian | $176.38K | 4.65% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $167.23K | 4.41% | 2026-06-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $112.32K | 2.96% | 2026-06-30 |
AQST Insider Trading (Form 4)
Latest: 2026-10-23Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-23 | John Cochran | Director | Other (J) | +62,229 | — | EDGAR | |
| 2026-10-16 | Daniel Barber | President and CEO | Sell (S) | −25,000 | $4.22 | -$105.6K | EDGAR |
| 2026-09-16 | Daniel Barber | President and CEO | Sell (S) | −25,000 | $4.82 | -$120.5K | EDGAR |
| 2026-09-11 | Sherry Korczynski | Chief Commercial Officer | Mixed | — | $3.94 | -$22.5K | EDGAR |
| 2026-09-10 | Peter E. Boyd | Chief People Officer | Exer (X) | +2,293 | $0.96 | $2.2K | EDGAR |
| 2026-09-09 | Daniel Barber | President and CEO | Exer (X) | +91,743 | $0.96 | $88.1K | EDGAR |
| 2026-09-08 | Cassie Jung | Chief Operating Officer | Exer (X) | +4,587 | $0.96 | $4.4K | EDGAR |
| 2026-08-18 | Daniel Barber | President and CEO | Sell (S) | −25,000 | $4.29 | -$107.2K | EDGAR |
| 2026-08-17 | Sherry Korczynski | Chief Commercial Officer | Tax (F) | −2,714 | $4.25 | -$11.5K | EDGAR |
| 2026-07-17 | Daniel Barber | President and CEO | Sell (S) | −25,000 | $4.01 | -$100.2K | EDGAR |
| 2026-06-24 | Julie Krop | Director | Mixed | — | $2.86 | -$107.6K | EDGAR |
| 2026-06-16 | Daniel Barber | President and CEO | Sell (S) | −25,000 | $4.16 | -$104.0K | EDGAR |
| 2026-06-12 | Marco Taglietti | Director | Grant (A) | +50,500 opt | — | EDGAR | |
| 2026-06-12 | Abigail L. Jenkins | Director | Grant (A) | −50,500 opt | — | EDGAR | |
| 2026-06-12 | Julie Krop | Director | Grant (A) | +50,500 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
AQST Insider Holdings
15 insiders · @ $3.97
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Daniel Barber | President and CEO | 627,317 | $2.49M | -$1.78M | 29 | 2026-10-16 |
| 2 | Stephen Wargacki | Chief Science Officer | 363,555 | $1.44M | $0 | 8 | 2025-03-11 |
| 3 | Peter E. Boyd | Chief People Officer | 284,024 | $1.13M | -$323.4K | 24 | 2026-09-10 |
| 4 | A Ernest Toth Jr | Chief Financial Officer | 283,460 | $1.13M | -$243.1K | 13 | 2026-05-07 |
| 5 | Carl N Kraus | Chief Medical Officer | 282,475 | $1.12M | -$141.9K | 6 | 2025-10-17 |
| 6 | Melina Cioffi | SVP, Regulatory Affairs | 273,200 | $1.08M | -$105.6K | 4 | 2026-05-18 |
| 7 | Sherry Korczynski | Chief Commercial Officer | 244,439 | $970.4K | -$111.4K | 9 | 2026-09-11 |
| 8 | Lori J Braender | Corporate Secretary | 231,042 | $917.2K | -$81.2K | 19 | 2026-05-11 |
| 9 | Cassie Jung | Chief Operating Officer | 208,833 | $829.1K | -$975.9K | 14 | 2026-09-08 |
| 10 | John Cochran | Director | 161,715 | $642.0K | $0 | 12 | 2026-10-23 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
AQST Board & Officers
As of SEC filings through Oct 23, 2026Directors 8
- Gregory B Brown · since Jul 24, 2018
- John Cochran · since Jul 24, 2018
- Julie Krop · since Feb 10, 2021
- Marco Taglietti · since Feb 10, 2021
- Timothy E Morris · on file since Aug 2022
- Abigail L. Jenkins · since Apr 1, 2024
- Daniel Barber · listed since Aug 2026
- Richard J Daly · since Oct 15, 2026
Officers 10
- Daniel Barber · President and CEO · listed since Aug 2022
- A Ernest Toth Jr · Chief Financial Officer · listed since Mar 2025
- Cassie Jung · Chief Operating Officer · listed since Sep 2026
- Carl N Kraus · Chief Medical Officer · since Jun 26, 2023
- Sherry Korczynski · Chief Commercial Officer · listed since Aug 2025
- Matthew W. Davis · Chief Development Officer · since Nov 3, 2025
- Peter E. Boyd · Chief People Officer · listed since Dec 2025
- Matthew J. Greenhawt · Chief Medical Officer · since Mar 2, 2026
- Thomas A. Zalewski · Chief Legal Officer · since Apr 2, 2026
- Melina Cioffi · SVP, Regulatory Affairs · since Apr 25, 2025
Changes in the last 10 years (65)
| Oct 15, 2026 | Richard J Daly became a director |
| Sep 8, 2026 | Cassie Jung first listed as Chief Operating Officer in an SEC filing |
| Aug 18, 2026 | Daniel Barber first listed as a director in an SEC filing |
| May 11, 2026 | Lori J Braender reported in an SEC filing no longer being Corporate Secretary |
| Apr 13, 2026 | Lori J Braender listed as Corporate Secretary (previously Chief Legal Officer) in SEC filings |
| Apr 2, 2026 | Thomas A. Zalewski became Chief Legal Officer |
| Mar 11, 2026 | Daniel Barber no longer listed as a director in SEC filings |
| Mar 2, 2026 | Matthew J. Greenhawt became Chief Medical Officer |
| Dec 5, 2025 | Peter E. Boyd listed as Chief People Officer (previously SVP IT, HR, & Communications) in SEC filings |
| Nov 3, 2025 | Matthew W. Davis became Chief Development Officer |
| Sep 22, 2025 | Daniel Barber first listed as a director in an SEC filing |
| Sep 8, 2025 | Peter E. Boyd listed as SVP IT, HR, & Communications (previously See Remark) in SEC filings |
| Sep 8, 2025 | Cassie Jung reported in an SEC filing no longer being Chief Operating Officer |
| Aug 15, 2025 | Sherry Korczynski listed as Chief Commercial Officer (previously SVP Sales and Marketing) in SEC filings |
| Apr 25, 2025 | Melina Cioffi became SVP, Regulatory Affairs |
| Mar 11, 2025 | Lori J Braender listed as Chief Legal Officer (previously SVP, General Counsel) in SEC filings |
| Mar 11, 2025 | A Ernest Toth Jr listed as Chief Financial Officer (previously SVP, Chief Financial Officer) in SEC filings |
| Nov 27, 2024 | Cassie Jung listed as Chief Operating Officer (previously SVP, Operations) in SEC filings |
| Nov 1, 2024 | The company announced the departure of Santo J Costa from the board in an SEC filing |
| Jun 3, 2024 | Sherry Korczynski became SVP Sales and Marketing |
| May 13, 2024 | Stephen Wargacki listed as Chief Science Officer (previously SVP, Research & Development) in SEC filings |
| Apr 1, 2024 | Abigail L. Jenkins became a director |
| Jun 26, 2023 | Carl N Kraus became Chief Medical Officer |
| Mar 9, 2023 | Peter E. Boyd listed as See Remark (previously SVP-Bus. Process & Info. Tech.) in SEC filings |
| Jan 1, 2023 | Stephen Wargacki became SVP, Research & Development |
| Jan 1, 2023 | Cassie Jung became SVP, Operations |
| Nov 8, 2022 | A Ernest Toth Jr listed as SVP, Chief Financial Officer (previously Interim CFO) in SEC filings |
| Sep 8, 2022 | Kenneth Truitt first on file as Chief Medical Officer |
| Aug 17, 2022 | Timothy E Morris first on file as a director |
| Aug 8, 2022 | Daniel Barber listed as President and CEO (previously SVP-Chief Operating Officer) in SEC filings |
| May 17, 2022 | The company announced the departure of Keith J Kendall as CEO and President in an SEC filing |
| Mar 16, 2021 | Douglas K Bratton no longer listed as a director in SEC filings |
| Feb 10, 2021 | Marco Taglietti became a director |
| Feb 10, 2021 | Julie Krop became a director |
| Dec 31, 2020 | A Ernest Toth Jr became Interim CFO |
| Sep 20, 2019 | Ken W. Marshall listed as SVP, Chief Commercial Officer (previously Commercial Leader) in SEC filings |
| Aug 13, 2019 | Peter E. Boyd listed as SVP-Bus. Process & Info. Tech. (previously SVP-Operations/Value Delivery) in SEC filings |
| May 10, 2019 | Daniel Barber listed as SVP-Chief Operating Officer (previously SVP-Chief Strategy/Dev Officer) in SEC filings |
| Jan 2, 2019 | Gary H Slatko became SVP, Chief Medical Officer |
| Sep 10, 2018 | Lori J Braender became SVP, General Counsel |
| Aug 17, 2018 | Alexander Mark Schobel no longer listed as a director in SEC filings |
| Jul 26, 2018 | Bratton Capital Management, L.P. first on file as a 10% owner |
| Jul 26, 2018 | Bratton Capital Inc. first on file as a 10% owner |
| Jul 24, 2018 | Theresa Wood became SVP-HR and Org. Development |
| Jul 24, 2018 | Santo J Costa became a director |
| Jul 24, 2018 | Peter E. Boyd became SVP-Operations/Value Delivery |
| Jul 24, 2018 | Nancy Lurker became a director |
| Jul 24, 2018 | MonoSol Rx Genpar, L.P. became a 10% owner |
| Jul 24, 2018 | MonoLine RX, L.P. became a 10% owner |
| Jul 24, 2018 | MonoLine RX III, L.P. became a 10% owner |
| Jul 24, 2018 | MonoLine RX II, L.P. became a 10% owner |
| Jul 24, 2018 | MonoLine Partners, L.P. became a 10% owner |
| Jul 24, 2018 | MRX Partners, LLC became a 10% owner |
| Jul 24, 2018 | Ken W. Marshall became Commercial Leader |
| Jul 24, 2018 | Keith J Kendall became a director |
| Jul 24, 2018 | Keith J Kendall became CEO and President |
| Jul 24, 2018 | John T. Maxwell became SVP-Chief Financial Officer |
| Jul 24, 2018 | John Cochran became a director |
| Jul 24, 2018 | James S Scibetta became a director |
| Jul 24, 2018 | Gregory B Brown became a director |
| Jul 24, 2018 | Douglas K Bratton became a director |
| Jul 24, 2018 | Douglas K Bratton became a 10% owner |
| Jul 24, 2018 | Daniel Barber became SVP-Chief Strategy/Dev Officer |
| Jul 24, 2018 | Alexander Mark Schobel became a director |
| Jul 24, 2018 | Alexander Mark Schobel became Chief Innovation/Tech Officer |
Not reported recently (19)
- Stephen Wargacki · Last reported as Chief Science Officer in an SEC filing dated Mar 11, 2025
- Douglas K Bratton · Last reported as a 10% owner in an SEC filing dated Dec 4, 2024
- Alexander Mark Schobel · Last reported as Chief Innovation/Tech Officer in an SEC filing dated Oct 2, 2024
- Ken W. Marshall · Last reported as SVP, Chief Commercial Officer in an SEC filing dated Aug 9, 2023
- Kenneth Truitt · Last reported as Chief Medical Officer in an SEC filing dated Sep 8, 2022
- Theresa Wood · Last reported as SVP-HR and Org. Development in an SEC filing dated Mar 14, 2022
- Keith J Kendall · Last reported as a director in an SEC filing dated Mar 14, 2022
- Nancy Lurker · Last reported as a director in an SEC filing dated Jun 17, 2021
- James S Scibetta · Last reported as a director in an SEC filing dated Jun 17, 2021
- MonoSol Rx Genpar, L.P. · Last reported as a 10% owner in an SEC filing dated Mar 16, 2021
- MonoLine RX II, L.P. · Last reported as a 10% owner in an SEC filing dated Mar 16, 2021
- MonoLine RX III, L.P. · Last reported as a 10% owner in an SEC filing dated Mar 16, 2021
- MonoLine RX, L.P. · Last reported as a 10% owner in an SEC filing dated Mar 16, 2021
- MRX Partners, LLC · Last reported as a 10% owner in an SEC filing dated Mar 16, 2021
- Bratton Capital Management, L.P. · Last reported as a 10% owner in an SEC filing dated Mar 16, 2021
- MonoLine Partners, L.P. · Last reported as a 10% owner in an SEC filing dated Mar 16, 2021
- Bratton Capital Inc. · Last reported as a 10% owner in an SEC filing dated Mar 16, 2021
- John T. Maxwell · Last reported as SVP-Chief Financial Officer in an SEC filing dated Aug 19, 2020
- Gary H Slatko · Last reported as SVP, Chief Medical Officer in an SEC filing dated Mar 18, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
AQST Proposed Insider Sales (Form 144)
Latest: 2026-09-15
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
3 filings
· $396K notice value
· 2 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Daniel Barber (2, $350K) · Sherry M. Korczynski (1, $46K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-15 | Daniel Barber | Director, Officer | 50,000 | $244.0K | 2026-09-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-09-09 | Sherry M. Korczynski | Officer | 8,750 | $45.6K | 2026-09-09 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-17 | Daniel Barber | Officer | 25,000 | $106.2K | 2026-08-17 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-15 | Daniel Barber | Officer | 25,000 | $101.0K | 2026-07-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-23 | JULIE KROP | Director | 25,000 | $118.0K | 2026-06-23 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-15 | Daniel Barber | Officer | 25,000 | $104.2K | 2026-06-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-05-15 | Daniel Barber | Officer | 8,257 | $39.1K | 2026-05-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-11-17 | Carl N. Kraus | Affiliate | 53,100 | $286.2K | 2025-11-17 | J.P. Morgan Securities LLC | — | EDGAR |
| 2025-10-15 | Carl N. Kraus | Officer | 40,544 | $278.9K | 2025-10-15 | J.P. Morgan Securities LLC | — | EDGAR |
| 2025-10-15 | CASSIE JUNG | Officer | 67,575 | $464.9K | 2025-10-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
26 ETFs hold AQST
25 shown · $49.21M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $15.8M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $11.0M | $74.6B | 2026-10-23 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $5.9M | — | 2026-09-30 |
| 4 | XPH State Street® SPDR® S&P® Pharmaceuticals ETF | SPDR (State Street) | 1.04% | $4.6M | $439.0M | 2026-10-23 |
| 5 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.02% | $2.9M | — | 2026-09-30 |
| 6 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.02% | $2.6M | $13.9B | 2026-10-23 |
| 7 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.01% | $1.5M | $13.7B | 2026-10-23 |
| 8 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.11% | $1.3M | $1.2B | 2026-10-23 |
| 9 | SURI Simplify Propel Opportunities ETF | Nport | 1.50% | $1.2M | — | 2026-06-30 |
| 10 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $663,884 | $96.5B | 2026-10-23 |
| 11 | FSCC Federated Hermes MDT Small Cap Core ETF | Nport | 0.23% | $649,125 | — | 2026-05-31 |
| 12 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.02% | $290,324 | — | 2026-09-30 |
| 13 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $206,226 | — | 2026-10-26 |
| 14 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.01% | $201,840 | — | 2026-09-30 |
| 15 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.00% | $138,292 | $20.4B | 2026-10-23 |
| 16 | PILL Direxion Daily Pharmaceutical & Medical Bull 3X ETF | Direxion | 0.76% | $111,012 | — | 2026-10-26 |
| 17 | QQQS Invesco NASDAQ Future Gen 200 ETF | Invesco | 0.45% | $90,404 | — | 2026-10-24 |
| 18 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $47,332 | — | 2026-09-30 |
| 19 | IBBQ Invesco Nasdaq Biotechnology ETF | Invesco | 0.03% | $38,936 | — | 2026-10-24 |
| 20 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.01% | $24,515 | — | 2026-10-26 |
| 21 | BIB ProShares Ultra NASDAQ Biotechnology | ProShares | 0.02% | $19,906 | — | 2026-10-26 |
| 22 | URTY ProShares UltraPro Russell2000 | ProShares | 0.01% | $18,802 | — | 2026-10-26 |
| 23 | MSSM Morgan Stanley Pathway Small-Mid Cap Equity ETF | Nport | 0.00% | $16,193 | — | 2026-05-31 |
| 24 | UWM ProShares Ultra Russell2000 | ProShares | 0.01% | $13,200 | — | 2026-10-26 |
| 25 | HDG ProShares Hedge Replication ETF | ProShares | 0.00% | $520 | — | 2026-10-26 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.65
TTM Revenue
$54.09M
TTM Net Income
$-78.23M
TTM Op. Cash Flow
$-45.37M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $13.82M | $-22.86M | $-0.18 | $-9.44M |
| Q1 '26 | 2026-03-31 | $14.45M | $-8.06M | $-0.07 | $-14.81M |
| Q4 '25 | 2025-12-31 | $13.02M | $-31.86M | $-0.27 | $-8.47M |
| Q3 '25 | 2025-09-30 | $12.81M | $-15.45M | $-0.14 | $-12.65M |
| Q2 '25 | 2025-06-30 | $10.00M | $-13.55M | $-0.14 | $-7.91M |
| Q1 '25 | 2025-03-31 | $8.72M | $-22.93M | $-0.24 | $-23.40M |
| Q4 '24 | 2024-12-31 | $11.87M | $-17.05M | $-0.19 | $-6.49M |
| Q3 '24 | 2024-09-30 | $13.54M | $-11.51M | $-0.13 | $-11.88M |
| Q2 '24 | 2024-06-30 | $20.10M | $-2.75M | $-0.03 | $-7.01M |
| Q1 '24 | 2024-03-31 | $12.05M | $-12.83M | $-0.17 | $-10.38M |
| Q4 '23 | 2023-12-31 | $13.21M | $-8.11M | $-0.13 | $-4.94M |
| Q3 '23 | 2023-09-30 | $13.00M | $-2.04M | $-0.03 | $-2.35M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-11
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
8.82
EV/EBITDA
—
EV/Sales
7.93
ROE
—
ROA
-59.2%
Div Yield
0.00%
FCF Yield
-9.51%
Debt/Equity
—
Current Ratio
—
Market Cap
$476.88M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
28.75M
SI % of Float
26.70%
Days to Cover
13.06
Short Vol Ratio
61.0%
Free Float
107.68M
Float %
85.8%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14